Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SIG +12.7%, ALK +4.9% (guidance), LOVE +2.4%, USB +0.6% (guidance; $5 billion common stock repurchase program, increase to quarterly common stock dividend)
Other news:
- NTGR +25.4% (settlement agreement with TP-Link Systems; raises Q3 revenue guidance)
- AURA +7.5% (Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma)
- BEEP +6.4% (authorizes $10 mln buyback plan)
- SMMT +6.3% (prices offering of 10.35 mln shares of common stock at $22.70 per share)
- BTG +4.4% (agrees on terms with Mali Government Relating to the Framework for the Fekola Complex; Approvals for Fekola Regional and Fekola Underground to be Expedited)
- MCRB +3.8% (Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant)
- ASND +2.5% (receives FDA Orphan Drug exclusivity for YORVIPATH)
- CEVA +2% (renews share repurchase authorization)
- IVZ +1.8% (prelim AUM)
- APAM +1.6% (prelim AUM)
- RWT +1.4% (increases dividend)
- BBW +1.4% (new repurchase program of $100 mln)